Immunotherapy for human cancer using heat shock protein-peptide complexes

Current Oncology Reports

Volumn 7, Issue 2, 2005, Pages 104-108

  Srivastava, Pramod K ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 96; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; TUMOR VACCINE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DENDRITIC CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOGENICITY; KIDNEY CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NONHUMAN; REVIEW;

EID: 16844371156     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0035-8     Document Type: Review

References (37)

1. Srivastava P: Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002, 20: 95-425.
2. Srivastava PK, Udono H, Blachere NE, Li Z: Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994, 39:93-98.
3. Zhu X, Zhao Y, Burkholder WF, et al.: Structural analysis of substrate binding by the molecular chaperone DnaK. Science 1996, 272:1606-1614.
4. MacAry PA, Javid B, Floto RA, et al.: HSP70 peptide binding mutants separate antigen delivery from dendritic cell stimulation. Immunity 2004, 20:95-106.
5. Gidalevitz T, Biswas C, Ding H, et al.: Identification of the N-terminal peptide binding site of glucose-regulated protein 94. J Biol Chem 2004, 279: 6543-16552.
6. Baker-LePain JC, Sarzotti M, Fields TA, et al.: GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. J Exp Med 2002, 196: 447-1459.
7. Grossmann ME, Madden BJ, Gao F, et al.: Proteomics shows Hsp70 does not bind peptide sequences indiscriminately in vivo. Exp Cell Res 2004, 297:108-117.
8. Blond-Elguindi S, Cwirla SE, Dower WJ, et al.: Affinity panning of a library of peptides displayed on bacteriophages reveals the binding specificity of BiP. Cell 1993, 75: 17-728.
9. Podack Yamazaki K, Nguyen T, Podack ER: Cutting edge: Tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J Immunol 1999, 163:5178-5182.
10. Massa C, Guiducci C, Arioli I, et al.: Enhanced efficacy of tumor cell vaccines transfected with secretable hsp70. Cancer Res 2004, 64:1502-1508.
11. Tobian AA, Canaday DH, Boom WH, Harding CV: Bacterial heat shock proteins promote CD91-dependent class I MHC cross-presentation of chaperoned peptide to CD8+ T cells by cytosolic mechanisms in dendritic cells versus vacuolar mechanisms in macrophages. J Immunol 2004, 172:5277-5286.
12. Tobian AA, Canaday DH, Harding CV: Bacterial heat shock proteins enhance class II MHC antigen processing and presentation of chaperoned peptides to CD4+ T cells. J Immunol, 2004, 173: 130-5137.
13. SenGupta D, Norris PJ, Suscovich TJ, et al.: Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II. J Immunol 2004, 173:1987-1993.
14. Kumaraguru U, Gierynska M, Norman S, et al.: Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection. J Virol 2002, 76:136-141.
15. Kumaraguru U, Suvas S, Biswas PS, et al.: Concomitant helper response rescues otherwise low avidity CD8+ memory CTLs to become efficient effectors in vivo. J Immunol 2004, 172:3719-3124.
16. Doody AD, Kovalchin JT, Mihalyo MA, et al.: Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8(+) T cell effector function. J Immunol 2004, 172:6087-6092.
17. Rapp UK, Kaufmann SH: DNA vaccination with gp96-peptide fusion proteins induces protection against an intracellular bacterial pathogen. Int Immunol 2004, 16:597-605.
18. Wang XY, Kazim L, Repasky EA, Subjeck JR: Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease. Int J Cancer 2003, 105:226-231.
19. Manjili MH, Wang XY, Chen X, et al.: HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 2003, 171:4054-4061.
20. Ito A, Shinkai M, Honda H, et al.: Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol Immunother 2003, 52:80-88.
21. Graner MW, Zeng Y, Feng H, Katsanis E: Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother 2003, 52: 26-234.
22. Binder RJ, Han DK, Srivastava PK: CD91: a receptor for heat shock protein gp96. Nat Immunol 2000, 1:151-155.
23. Basu S, Binder RJ, Ramalingam T, Srivastava PK: CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001, 14:303-313.
24. Binder RJ, Vatner R, Srivastava P: The heat-shock protein receptors: some answers and more questions. Tissue Antigens 2004, 64:442-445.
25. Binder RJ, Srivastava PK: Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc Natl Acad Sci U S A 2004, 101:6128-6133.
26. Orr AW, Pedraza CE, Pallero MA, et al.: Low density lipoprotein receptor-related protein is a calreticulin coreceptor that signals focal adhesion disassembly. J Cell Biol 2003, 161: 179-1189.
27. Stebbing J, Gazzard B, Kim L, et al.: The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected 'true' long-term nonprogressors. Blood 2003, 101: 000-4004.
28. Stebbing J, Gazzard B, Portsmouth S, et al.: Disease associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor. Blood 2003, 102: 806-1814.
29. Berwin B, Hart JP, Rice S, et al.: Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells. EMBO J 2003, 22:6127-6136.
30. Berwin B, Delneste Y, Lovingood RV, et al.: SREC-I, a type F scavenger receptor, is an endocytic receptor for calreticulin. J Biol Chem 2004, 279:51250-51257.
31. Radsak MP, Hilf N, Singh-Jasuja H, et al.: The heat shock protein gp96 binds to human neutrophils and monocytes and stimulates effector functions. Blood 2003, 101:2810-2815.
32. Castelli C, Ciupitu AM, Rini F, et al.: Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 2001, 61:222-227.
33. Noessner E, Gastpar R, Milani V, et al.: Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol 2002, 169:5424-5432.
34. Staib F, Distler M, Bethke K, et al.: Cross-presentation of human melanoma peptide antigen MART-1 to CTLs from in vitro reconstituted gp96/MART-1 complexes. Cancer Immun 2004, 4:3.
35. Belli F, Testori A, Rivoltini L, et al.: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002, 20:4169-4180.
36. Mazzaferro V, Coppa J, Carrabba MG, et al.: Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003, 9:3235-3245.
37. Rivoltini L, Castelli C, Carrabba M, et al.: Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J Immunol 2003, 171:3467-3474.